Gene amplification is the most common aberration of the FGFR2 gene amongst gastrointestinal cancers [16], with differences between early and advanced stages: amongst the early stages, FGFR2 amplifications are associated with larger tumor size (T stage) and major lymph node dissemination, which can lead to poorer patient outcomes, including inferior overall survival. This evidence concerns the gene FGFR2 and neoplasm.